Cargando…
CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells
Autores principales: | Morishima, Chihiro, McNeel, Douglas G, Patel, Manish R, Kohrt, Holbrook E, Waldmann, Thomas A, Thompson, John A, Conlon, Kevin C, Sondel, Paul M, Wakelee, Heather A, Apodaca, Minjun C, Fling, Steven P, Disis, Mary L, Creekmore, Stephen P, Miller, Jeffrey S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649400/ http://dx.doi.org/10.1186/2051-1426-3-S2-P203 |
Ejemplares similares
-
CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells
por: Morishima, Chihiro, et al.
Publicado: (2014) -
CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
por: Margolin, Kim, et al.
Publicado: (2014) -
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
por: Miyazaki, Takahiro, et al.
Publicado: (2021) -
Preliminary validation of nCounter PanCancer immune profiling of FFPE slides and pbmc in CITN-05, a CITN study of the immunological effects of an IDO1 inhibitor in patients with ovarian carcinoma
por: Dennis, Lucas, et al.
Publicado: (2015) -
IL-15 in the Combination Immunotherapy of Cancer
por: Waldmann, Thomas A., et al.
Publicado: (2020)